Wall Street is positive on Recursion Pharmaceuticals Inc (RXRX). On average, analysts give the stock a Buy rating. The average price target is $15.285, which means analysts expect the stock to climb by 117.12% over the next twelve months. That average ranking earns the stock an Analyst Rating of 26, which is better than 26% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating RXRX a Buy today. Find out what this means to you and get the rest of the rankings on RXRX!